Glucagon-like peptide 1 (GLP-1) and analogues are being evaluated as a new therapeutic
principle for the treatment of type 2 diabetes. GLP-1 suppresses glucagon secretion, which …

Previous studies have suggested that glucagon-like peptide-1 (GLP-1)(7–36 amide) may
have the direct effect of increasing insulin sensitivity in healthy man. To evaluate this …

Objective: Glucagon-like peptide-1 (GLP-1) is insulinotropic, but its effect on the α-cell is less
clear. We investigated the dose-response relationship for GLP-1-induced glucagon …

Glucagon‐like peptide‐1 (7–36) amide (GLP‐1) is released from the gut into the circulation
after meals and is the most potent physiological insulinotropic hormone in man. In contrast to …

GLP-1 lowers blood glucose in fasting type 2 diabetic patients. To clarify the relation of the
effect of GLP-1 to obesity, blood glucose, β-cell function, and insulin sensitivity, GLP-1 (1.2 …

OBJECTIVE Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via
effects on pancreatic β-and α-cells. Previous studies have focused on the improvements in β …

Administration of the truncated glucagon-like peptide 1 (GLP-1) has been considered for
treatment of noninsulin-dependent diabetes mellitus (NIDDM). We studied its …

Abstract Background Glucagon-like peptide-1 (GLP-1) and its agonists are under
assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which …

Although it is well established that glucagon-like peptide 1 (7-36) amide (GLP-1) is a potent
stimulator of insulin secretion, its effects on insulin action and glucose effectiveness are less …

Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that augments
insulin secretion in response to meals and lowers blood glucose levels in both type 1 and …